Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor

Journal of Controlled Release

Volumn 164, Issue 2, 2012, Pages 213-220

  Lee, Sangbin ^a   Kim, Jiyeon ^a   Shim, Gayong ^b   Kim, Sunil ^b   Han, Su Eun ^a   Kim, Kwangmeyung ^c   Kwon, Ick Chan ^c   Choi, Yongseok ^a   Kim, Young Bong ^d   Kim, Chan Wha ^a   Oh, Yu Kyoung ^b  

^a Korea University   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Konkuk University   (South Korea)

Author keywords

Anticancer drug; Edelfosine; Integrin receptor; Liposome; Tetraiodothyroacetic acid

Indexed keywords

ANTICANCER DRUG; BACKGROUND LEVEL; EDELFOSINE; HIGH DENSITY; INTEGRIN RECEPTORS; INTEGRINS; INTRAVENOUS ADMINISTRATION; LOW DENSITY; LYSOPHOSPHATIDYL-CHOLINE; MELANOMA CELLS; PEGYLATED LIPIDS; PEGYLATED LIPOSOMES; SYSTEMIC ADMINISTRATION; THERAPEUTIC EFFICACY; THYROID HORMONES; TUMOR CELLS; TUMOR SITE; TUMOR TISSUES;

CELLS; CYTOLOGY; DRUG DELIVERY; HISTOLOGY; LIPOSOMES; MAMMALS; MOLECULAR IMAGING; NANOPARTICLES; PHOSPHOLIPIDS;

TUMORS;

ACETIC ACID; EDELFOSINE; INTEGRIN RECEPTOR; LIPID; LIPOSOME; TETRAIODOTHYROACETIC ACID; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CELL SURVIVAL; CONTROLLED STUDY; COVALENT BOND; DENSITY; DRUG DELIVERY SYSTEM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INOCULATION; MELANOMA CELL; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRIN ALPHAVBETA3; LIPOSOMES; MICE; MICE, NUDE; NEOPLASMS; PHOSPHOLIPID ETHERS; THYROXINE;

EID: 84869493371     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.05.043     Document Type: Article

References (54)

1. F. Danhier, B. Vroman, N. Lecouturier, N. Crokart, V. Pourcelle, H. Freichels, C. Jerome, J. Marchand-Brynaert, O. Feron, and V. Preat Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel J. Control. Release 140 2009 166 173
2. B. Haley, and E. Frenkel Nanoparticles for drug delivery in cancer treatment Urol. Oncol. 26 2008 57 64
3. S.J. Lim, J.N. Cormier, B.W. Feig, P.F. Masfield, R.S. Benjamin, J.R. Griffin, J.L. Chase, P.W. Pisters, R.E. Pollock, and K.K. Hunt Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis Ann. Surg. Oncol. 14 2007 2309 2318
4. A. Gabizon, D. Tzemach, J. Gorin, L. Mak, Y. Amitay, H. Shmeeda, and S. Zalipsky Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models Cancer Chemother. Pharmacol. 66 2010 43 52
5. S.J. Chiu, S. Liu, D. Perrotti, G. Marcucci, and R.J. Lee Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes J. Control. Release 112 2006 199 207
6. H.D. Han, L.S. Mangala, J.W. Lee, M.M. Shahzad, H.S. Kim, D. Shen, E.J. Nam, E.M. Mora, R.L. Stone, C. Lu, S.J. Lee, J.W. Roh, A.M. Nick, G. Lopez-Berestein, and A.K. Sood Targeted gene silencing using RGD-labeled chitosan nanoparticles Clin. Cancer Res. 16 2010 3910 3922
7. B. Yu, H.C. Tai, W. Xue, L.J. Lee, and R.J. Lee Receptor-targeted nanocarriers for therapeutic delivery to cancer Mol. Membr. Biol. 27 2010 286 298
8. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22
9. M. Tucci, R. De Palma, L. Lombardi, G. Rodolico, L. Berrino, F. Dammacco, and F. Silvestris β(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells Cancer Res. 69 2009 6738 6746
10. Y. Wang, X. Wang, Y. Zhang, S. Yang, J. Wang, X. Zhang, and Q. Zhang RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells J. Drug Target. 17 2009 459 467
11. J. Bai, J. Zhang, J. Wu, L. Shen, J. Jeng, J. Ding, Y. Wu, Z. Gong, A. Li, S. Xu, J. Zhou, and G. Li JWA regulates melanoma metastasis by integrin α(V)β(3) signaling Oncogene 29 2010 1227 1237
12. A.J. Beer, and M. Schwaiger PET imaging of αvβ3 expression in cancer patients Methods Mol. Biol. 680 2011 183 200
13. J.J. Bergh, H.Y. Lin, L. Lansing, S.N. Mohamed, F.B. Davis, S. Mousa, and P.J. Davis Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis Endocrinology 146 2005 2864 2871
14. S.A. Mousa, J.J. Bergh, E. Dier, A. Rebbaa, L.J. O'Connor, M. Yalcin, A. Aljada, E. Dyskin, F.B. Davis, H.Y. Lin, and P.J. Davis Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor Angiogenesis 11 2008 183 190
15. M. Yalcin, E. Dyskin, L. Lansing, D.J. Bharali, S.S. Mousa, A. Bridoux, A.H. Hercbergs, H.Y. Lin, F.B. Davis, G.V. Glinsky, A. Glinskii, J. Ma, P.J. Davis, and S.A. Mousa Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid J. Clin. Endocrinol. Metab. 95 2010 1972 1980
16. M. Yalcin, D.J. Bharali, L. Lansing, E. Dyskin, S.S. Mousa, A. Hercbergs, F.B. Davis, P.J. Davis, and S.A. Mousa Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts Anticancer Res. 29 2009 3825 3831
17. G. Shim, S.E. Han, Y.H. Yu, S. Lee, H.Y. Lee, K. Kim, I.C. Kwon, T.G. Park, Y.B. Kim, Y.S. Choi, C.W. Kim, and Y.K. Oh Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug J. Control. Release 155 2011 60 66
18. M.S. Suh, G. Shim, H.Y. Lee, S.E. Han, Y.H. Yu, Y. Choi, K. Kim, I.C. Kwon, K.Y. Weon, Y.B. Kim, and Y.K. Oh Anionic amino acid-derived cationic lipid for siRNA delivery J. Control. Release 140 2009 268 276
19. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic uptake of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
20. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
21. S. Acharya, and S.K. Sahoo PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect Adv. Drug Deliv. Rev. 63 2011 170 183
22. K. Maruyama Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects Adv. Drug Deliv. Rev. 63 2011 161 169
23. P.C. Brooks, A.M. Montgomery, M. Rosenfeld, R.A. Reisfeld, T. Hu, G. Klier, and D.A. Cheresh Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 79 1994 1157 1164
24. S. Moretti, C. Pinzi, E. Berti, A. Spallanzani, A. Chiarugi, V. Boddi, U.M. Reali, and B. Gianotti In situ expression of transforming growth factor β is associated with melanoma progression and correlates with Ki67, HLA-DR and β3 integrin expression Melanoma Res. 7 1997 313 321
25. C.L. Gladson, S. Hancock, M.M. Arnold, O.M. Faye-Petersen, R.P. Castleberry, and D.R. Kelly Stage-specific expression of integrin αvβ3 in neuroblastic tumors Am. J. Pathol. 148 1996 1423 1434
26. F.C. Gaertner, M. Schwaiger, and A.J. Beer Molecular imaging of αvß3 expression in cancer patients Q. J. Nucl. Med. Mol. Imaging 54 2010 309 326
27. L.E. van Vlerken, T.K. Vyas, and M.M. Amiji Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery Pharm. Res. 24 2007 1405 1414
28. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
29. A.S. Manjappa, K.R. Chaudhari, M.P. Venkataraju, P. Dantuluri, B. Nanda, C. Sidda, K.K. Sawant, and R.S. Murthy Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor J. Control. Release 151 2011 2 22
30. R. Ria, A. Reale, A. Castrovilli, G. Mangialardi, F. Dammacco, D. Ribatti, and A. Vacca Angiogenesis and progression in human melanoma Dermatol. Res. Pract. 2010 2010 185687
31. M. Gutiérrez, P. Isa, C. Sánchez-San Martin, J. Pérez-Vargas, R. Espinosa, C.F. Arias, and S. López Different rotavirus strains enter MA104 cells through different endocytic pathways: the role of clathrin-mediated endocytosis J. Virol. 84 2010 2010 9161 9169
32. T. Gianni, V. Gatta, and G. Campadelli-Fiume αVβ3-integrin routes herpes simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin 2 Proc. Natl. Acad. Sci. U. S. A. 107 2010 22260 22265
33. A.H. van der Luit, S.R. Vink, J.B. Klarenbeek, D. Perrissoud, E. Solary, M. Verheij, and W.J. van Blitterswijk A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells Mol. Cancer Ther. 6 2007 2337 2345
34. I. Ahmad, J.J. Filep, J.C. Franklin, A.S. Janoff, G.R. Masters, J. Pattassery, A. Peters, J.J. Schupsky, Y. Zha, and E. Mayhew Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3- phosphocholine Cancer Res. 57 1997 1915 1921
35. T. Nieto-Miguel, R.I. Fonteriz, L. Vay, C. Gajate, S. Lopez-Hernandez, and F. Mollinedo Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells Cancer Res. 67 2007 10368 10378
36. F. Mollinedo, J. de la Iglesia-Vicente, C. Gajate, A. Estella-Hermoso de Mendoza, J.A. Villa-Pulgarin, M. de Frias, G. Roué, J. Gil, D. Colomer, M.A. Campanero, and M.J. Blanco-Prieto In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts Clin. Cancer Res. 16 2010 2046 2054
37. A.H. van der Luit, M. Budde, P. Ruurs, M. Verheij, and W.J. van Blitterswijk Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis J. Biol. Chem. 277 2002 39541 39547
38. W.J. van Blitterswijk, and M. Verheij Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects Curr. Pharm. Des. 14 2008 2061 2074
39. T. Nieto-Miguel, C. Gajate, and F. Mollinedo Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells J. Biol. Chem. 281 2006 14833 14840
40. H. Shmeeda, L. Mak, D. Tzemach, P. Astrahan, M. Tarshish, and A. Gabizon Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors Mol. Cancer Ther. 5 2006 818 824
41. Y.H. Bae, and K. Park Targeted drug delivery to tumors: myths, reality and possibility J. Control. Release 153 2011 198 205
42. J. Prakash, L. Beljaars, A.K. Harapanahalli, M. Zeinstra-Smith, A. Jager-Krikken, M. Hessing, H. Steen, and K. Poelstra Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/ insulin-like growth factor II receptor Int. J. Cancer 126 2010 1966 1981
43. Y. Bae, N. Nishiyama, and K. Kataoka In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments Bioconjug. Chem. 18 2007 1131 1139
44. A. Estella-Hermoso de Mendoza, M. Rayo, F. Mollinedo, and M.J. Blanco-Prieto Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization Eur. J. Pharm. Biopharm. 68 2008 207 213
45. S.R. Vink, W.J. van Blitterswijk, J.H. Schellens, and M. Verheij Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy Cancer Treat. Rev. 33 2007 191 202
46. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv. Drug Deliv. Rev. 61 2009 850 862
47. G.H. Heppner, and B.E. Miller Tumor heterogeneity: biological implications and therapeutic consequences Cancer Metastasis Rev. 2 1983 5 23
48. A. Taherian, X. Li, Y. Liu, and T.A. Haas Differences in integrin expression and signaling within human breast cancer cells BMC Cancer 11 2011 293
49. J.L. Luque-García, J.L. Martínez-Torrecuadrada, C. Epifano, M. Cañamero, I. Babel, and J.I. Casal Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis Proteomics 10 2010 940 952
50. F. Yuan, H.A. Salehi, Y. Boucher, U.S. Vasthare, R.F. Tuma, and R.K. Jain Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows Cancer Res. 54 1994 4564 4568
51. R. Kolhatkar, A. Lote, and H. Khambati Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors Curr. Drug Discov. Technol. 8 2011 197 206
52. F. Yuan, M. Leunig, S.K. Huang, D.A. Berk, D. Papahad-jopoulos, and R.K. Jain Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res. 54 1994 3352 3356
53. C. Wong, T. Stylianopoulos, J. Cui, J. Martin, V.P. Chauhan, W. Jiang, Z. Popovic, R.K. Jain, M.G. Bawendi, and D. Fukumura Multistage nanoparticle delivery system for deep penetration into tumor tissue Proc. Natl. Acad. Sci. U. S. A. 108 2011 2426 2431
54. J.M. Saul, A.V. Annapragada, and R.V. Bellamkonda A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers J. Control. Release 114 2006 277 287